Free Trial
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$2.40
-3.6%		$3.96
$2.12
▼
$71.50
$3.92M2.6395,661 shs46,530 shs
HIND
Vyome
$2.09
+3.0%		$2.11
$1.75
▼
$6.56
$14.67M1.5322,158 shs7,586 shs
IN8bio, Inc. stock logo
INAB
IN8bio
$1.34
-2.9%		$1.15
$0.88
▼
$2.73
$13.21M0.351,614 shs13,052 shs
Synlogic, Inc. stock logo
SYBX
Synlogic
$1.10
$1.17
$0.54
▼
$1.87
$13.47M0.6168,078 shs2 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
0.00%-18.92%-40.30%-60.40%-92.99%
HIND
Vyome
0.00%+9.42%-0.48%-7.11%-64.40%
IN8bio, Inc. stock logo
INAB
IN8bio
0.00%-4.29%+21.82%+0.75%-44.40%
Synlogic, Inc. stock logo
SYBX
Synlogic
0.00%-0.90%-9.84%+54.71%-36.60%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$2.40
-3.6%		$3.96
$2.12
▼
$71.50
$3.92M2.6395,661 shs46,530 shs
HIND
Vyome
$2.09
+3.0%		$2.11
$1.75
▼
$6.56
$14.67M1.5322,158 shs7,586 shs
IN8bio, Inc. stock logo
INAB
IN8bio
$1.34
-2.9%		$1.15
$0.88
▼
$2.73
$13.21M0.351,614 shs13,052 shs
Synlogic, Inc. stock logo
SYBX
Synlogic
$1.10
$1.17
$0.54
▼
$1.87
$13.47M0.6168,078 shs2 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
0.00%-18.92%-40.30%-60.40%-92.99%
HIND
Vyome
0.00%+9.42%-0.48%-7.11%-64.40%
IN8bio, Inc. stock logo
INAB
IN8bio
0.00%-4.29%+21.82%+0.75%-44.40%
Synlogic, Inc. stock logo
SYBX
Synlogic
0.00%-0.90%-9.84%+54.71%-36.60%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
2.00
Hold$30.001,150.00% Upside
HIND
Vyome
2.25
Hold$3.5067.46% Upside
IN8bio, Inc. stock logo
INAB
IN8bio
2.00
Hold$4.00198.51% Upside
Synlogic, Inc. stock logo
SYBX
Synlogic
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ERNA, HIND, INAB, and SYBX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2026
HIND
Vyome
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$3.50
9/3/2026
HIND
Vyome
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$3.50
7/29/2026
HIND
Vyome
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
IN8bio, Inc. stock logo
INAB
IN8bio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$580K6.74N/AN/A$7.64 per share0.31
HIND
Vyome
$320K45.85N/AN/A$0.67 per share3.12
IN8bio, Inc. stock logo
INAB
IN8bio
N/AN/AN/AN/A$2.82 per shareN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
$8K1,684.24N/AN/A$1.09 per share1.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
-$14.08M-$14.35N/AN/AN/AN/A-305.93%-169.86%11/6/2026 (Estimated)
HIND
Vyome
-$10.26M-$3.37N/AN/AN/A-3,024.84%-197.33%-138.14%N/A
IN8bio, Inc. stock logo
INAB
IN8bio
-$19.44M-$1.62N/AN/AN/AN/A-91.18%-76.93%11/5/2026 (Estimated)
Synlogic, Inc. stock logo
SYBX
Synlogic
-$23.36M-$0.06N/AN/AN/AN/A-26.47%-18.00%11/11/2026 (Estimated)

Latest ERNA, HIND, INAB, and SYBX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2026N/A
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
-$3.84N/AN/AN/AN/AN/A
11/5/2026Q3 2026
IN8bio, Inc. stock logo
INAB
IN8bio
-$0.3367N/AN/AN/AN/AN/A
8/12/2026Q2 2026
HIND
Vyome
N/A-$0.10N/A-$0.10N/A$0.27 million
8/6/2026Q2 2026
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
-$3.30-$3.40-$0.10-$3.40N/AN/A
8/6/2026Q2 2026
IN8bio, Inc. stock logo
INAB
IN8bio
-$0.3437-$0.25+$0.0937-$0.25N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
N/AN/AN/AN/AN/A
HIND
Vyome
N/AN/AN/AN/AN/A
IN8bio, Inc. stock logo
INAB
IN8bio
N/AN/AN/AN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
N/A
2.01
2.01
HIND
Vyome
N/A
4.37
4.37
IN8bio, Inc. stock logo
INAB
IN8bio
N/A
8.21
8.21
Synlogic, Inc. stock logo
SYBX
Synlogic
N/A
2.65
2.65

Institutional Ownership

CompanyInstitutional Ownership
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
70.55%
HIND
Vyome
22.06%
IN8bio, Inc. stock logo
INAB
IN8bio
92.05%
Synlogic, Inc. stock logo
SYBX
Synlogic
63.40%

Insider Ownership

CompanyInsider Ownership
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
0.53%
HIND
Vyome
33.00%
IN8bio, Inc. stock logo
INAB
IN8bio
14.50%
Synlogic, Inc. stock logo
SYBX
Synlogic
2.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
51.63 million1.62 millionNo Data
HIND
Vyome
187.02 million4.70 millionN/A
IN8bio, Inc. stock logo
INAB
IN8bio
189.86 million8.43 millionNot Optionable
Synlogic, Inc. stock logo
SYBX
Synlogic
8012.25 million11.39 millionNo Data

Recent News About These Companies

Synlogic (NASDAQ:SYBX) Shares Break Below Fifty Day Moving Average - What's Next?
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31072859
Reviewing Synlogic (NASDAQ:SYBX) and Oncobiologics (NASDAQ:OTLK)
September 16, 2026  |  defenseworld.netD
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Varex Imaging Corporation (Nasdaq – VREX), Synlogic, Inc. (OTC – SYBX), Bowman Consulting Group Ltd. (Nasdaq – BWMN), Nathan's Famous, Inc. (Nasdaq – NATH)
August 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/28/3352812/0/en/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-varex-imaging-corporation-nasdaq-vrex-synlogic-inc-otc-sybx-bowman-consulting-group-ltd-nasdaq-.html
SYBX Stock Alert: Halper Sadeh LLC is Investigating Whether Synlogic, Inc. is Obtaining a Fair Price for its Shareholders
August 10, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/08/10/10427797.htm
Synlogic and Caldera Therapeutics announce merger and $278 million private placement
July 29, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/synlogic-and-caldera-therapeutics-announce-merger-and-278-million-private-placement/ar-AA28Zdef
Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement
July 29, 2026  |  aol.comA
Synlogic's Strategic Crossroads: A Company in Limbo
February 10, 2026  |  aktiencheck.deA
Synlogic Challenges Nasdaq Delisting Notice
November 26, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/synlogic-challenges-nasdaq-delisting-notice?utm_source=marketbeat.com&utm_medium=referral
We Think Synlogic (NASDAQ:SYBX) Can Afford To Drive Business Growth
September 18, 2025  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/think-synlogic-nasdaq-sybx-afford-105816457.html
Synlogic, Inc. (SYBX) Latest Stock News & Headlines - Yahoo Finance
June 28, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/SYBX/news/
Synlogic's executive sells shares worth $2,802
February 5, 2025  |  msn.comhttps://www.msn.com/en-us/money/executive-leadership-and-management/synlogic-s-executive-sells-shares-worth-2-802/ar-AA1yq62c
Synlogic Reports Q3 2024 Financial Outcomes
November 14, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/synlogic-reports-q3-2024-financial-outcomes-1034015193
Synlogic, Inc.: Synlogic Reports Third Quarter 2024 Financial Results
November 13, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-11/63800545-synlogic-inc-synlogic-reports-third-quarter-2024-financial-results-399.htm
Synlogic Reports Third Quarter 2024 Financial Results
November 12, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/11/12/2979778/0/en/synlogic-reports-third-quarter-2024-financial-results.html
Synlogic preps phenylketonuria drug for phase 3 after mid-stage win
November 6, 2024  |  pharmaphorum.comP
Synlogic, Inc. (0A8U.L)
August 24, 2024  |  nz.finance.yahoo.comhttps://nz.finance.yahoo.com/quote/0A8U.L/news/
MIN.SG,0P0001I7V6,0 (MIN.SG)
August 16, 2024  |  nz.finance.yahoo.comhttps://nz.finance.yahoo.com/quote/MIN.SG/chart/
Maintaining Hold on Synlogic Amid Strategic Reassessment and Financial Uncertainty
August 14, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/maintaining-hold-on-synlogic-amid-strategic-reassessment-and-financial-uncertainty-1033683377
Synlogic, Inc.: Synlogic Reports Second Quarter 2024 Financial Results
August 8, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-08/62948190-synlogic-inc-synlogic-reports-second-quarter-2024-financial-results-399.htm
SYBX Stock Earnings: Synlogic Beats EPS for Q2 2024
August 8, 2024  |  investorplace.comhttps://investorplace.com/earning-results/2024/08/sybx-stock-earnings-synlogic-for-q2-of-2024/?cc=marketbeat&cp=pdtk

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A Generac home standby generator installed outside a residential house at dusk, connected to an electrical panel.
Generac Plugs Into Amazon for an $8B AI-Powered Deal
By Jeffrey Neal Johnson | September 18, 2026
Palantir logo displayed on a large screen with a world map and data visualizations in a control room setting.
Everyone in AI Is Quietly Copying Palantir's Playbook
By Chris Markoch | October 1, 2026
Digital illustration of a data center control room with monitors, cloud icons, and small robots linked by network graphics.
These 3 Agentic AI Stocks Have More Than Hype Behind Their Growth Stories
By Chris Markoch | September 19, 2026
Fabrinet, Dycom and Qualcomm: 3 AI Fallen Angels Wall Street Just Marked Down
Fabrinet, Dycom, and Qualcomm: 3 AI Fallen Angels Wall Street Just Marked Down
By Bridget Bennett | September 14, 2026
LightPath Technologies logo beside an optical lens, with a cleanroom worker and military jet blurred in the background.
LightPath’s Defense Pivot Could Send Shares Higher
By Thomas Hughes | September 15, 2026
Ernexa Therapeutics stock logo

Ernexa Therapeutics NASDAQ:ERNA

$2.40 -0.09 (-3.61%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$2.35 -0.05 (-2.25%)
As of 10/9/2026 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Vyome NASDAQ:HIND

$2.08 +0.06 (+2.71%)
As of 10/9/2026 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

IN8bio stock logo

IN8bio NASDAQ:INAB

$1.34 -0.04 (-2.90%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$1.36 +0.02 (+1.49%)
As of 10/9/2026 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications.

Synlogic stock logo

Synlogic NASDAQ:SYBX

$1.10 0.00 (0.00%)
As of 10/9/2026

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas